Adverse Effects of Hydroxychloroquine in Different Connective Tissue Disorders Used for Dermatological Purpose

Sarwat Abdus Salam Sarwat Abdus Salam; Humaira Talat

doi:10.70749/ijbr.v3i4.999

Authors

Sarwat Abdus Salam Department of Dermatology, Dr Ruth KM Pfau Civil Hospital, Karachi, Pakistan
Humaira Talat Department of Dermatology, Dr Ruth KM Pfau Civil Hospital, Karachi, Pakistan

DOI:

https://doi.org/10.70749/ijbr.v3i4.999

Keywords:

Autoimmune Disease, Hydroxychloroquine, Cutaneous Manifestation, Gastrointestinal Symptoms

Abstract

Introduction: Hydroxychloroquine (HCQ) is one of the most frequently used drugs in dermatology with a wide variety of uses. This study was conducted to determine adverse effects of HCQ when given in patients of auto immune disorders. Objectives: To determine frequency of adverse effects of hydroxychloroquine in all patients using hydroxychloroquine for different connective tissue disorders used for dermatological purpose. Study design and setting: Cross sectional study was conducted at the Department of Dermatology, Civil Hospital Karachi during the period from July 9, 2024 to January 8, 2025. Methodology: Patients aged 12 to 70 years of both genders already diagnosed cases of connective tissue disorder taking hydroxychloroquine for more than 3 months visiting derma OPD for follow-up check-up were enrolled using non-probability consecutive sampling technique. Study was conducted after approval of hospital ethical committee and written informed consent of patients. Demographic data was noted. Adverse effects of hydroxychloroquine were noted. Data was entered and analyzed using SPSS 22. Results: In our study 167 patients were enrolled with mean age of 37.52±16.6 years, minimum age was 12 years and maximum age was 37.52 years. There were 24% (40) male patients and 76% (127) were female patients. Mean duration of HCQ use was 2.34±0.88 years. Most common adverse effects noted in our study was dermatological manifestations including skin hyperpigmentation in 28.1% (47) patients followed by urticarial rash in 13.8% (23), second most common involved system was gastrointestinal system including nausea in 10.8% (18), diarrhea in 9% (15), headache in 9.6% (16), heart blocks were observed in 8.4% (14) patients least common adverse effects included were myopathy in 7.2% (12) and retinal toxicity in 3.6% (6) patients only. Conclusion: Cutaneous and gastrointestinal symptoms are most commonly reported adverse effected by HCQ when used in patients of autoimmune disease.

Downloads

Download data is not yet available.

References

Sachdeva M, Mufti A, Maliyar K, Lytvyn Y, Yeung J. Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment. J Am Acad Dermatol. 2020;83(2):579-86. https://doi.org/10.1016/j.jaad.2020.05.074

Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7(1):11-9. https://doi.org/10.1186/s40779-020-00240-0

Han Y, Yang H. The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): A Chinese perspective. J Med Virol. 2020;92(6):639-44. https://doi.org/10.1002/jmv.25749

Nirk EL, Reggiori F, Mauthe M. Hydroxychloroquine in rheumatic autoimmune disorders and beyond. EMBO Mol Med. 2020;12(8):e12476. https://doi.org/10.15252/emmm.202012476

Morrisette T, Lodise TP, Scheetz MH, Goswami S, Pogue JM, Rybak MJ. The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse. Infect Dis Ther. 2020;9(3):561-72. https://doi.org/10.1007/s40121-020-00325-2

Luo X, Peng Y, Ge W. A sensitive and optimized HPLC-FLD method for the simultaneous quantification of hydroxychloroquine and its two metabolites in blood of systemic lupus erythematosus patients. J Chromatogr Sci. 2020;58(7):600–5. https://doi.org/10.1093/chromsci/bmaa023

Bezerra EL, Vilar MJ, Neto PB, Sato EI. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52(10):3073-8. https://doi.org/10.1002/art.21358

Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res.2010; 62(1):775–84. https://doi.org/10.1002/acr.20133

Casado E. Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis.2006; 65:385–90. https://doi.org/10.1136/ard.2004.023200

Jourde-Chiche N, Mancini J, Dagher N. Antimalarial ototoxicity: an underdiagnosed complication? A study of spontaneous reports to the French pharmacovigilance network. Ann Rheum Dis.2012; 71(1):1586-91. https://doi.org/10.1136/annrheumdis-2011-201265

Fram G, Wang DD, Malette K, Villablanca P, Kang G, So K, et al. Cardiac Complications Attributed to Hydroxychloroquine: A Systematic Review of the Literature Pre-COVID-19. Curr Cardiol Rev. 2021;17(3):319-27. https://doi.org/10.2174/1573403x16666201014144022

Bahloul E, Jallouli M, Garbaa S. Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases. Lupus.2017 26(1):1304–8. https://doi.org/10.1177/0961203317700486

Sachdeva M, Mufti A, Maliyar K, Lytvyn Y, Yeung J. Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment. J Am Acad Dermatol. 2020 Aug;83(2):579-586. https://doi.org/10.1016/j.jaad.2020.05.074

Sardana K, Sinha S, Sachdeva S. Hydroxychloroquine in Dermatology and Beyond: Recent Update. Indian Dermatol Online J. 2020 May 10;11(3):453-464. https://doi.org/10.4103/idoj.idoj_280_20

Pelle M, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol. 2002;138 (9):1231–3. https://doi.org/10.1001/archderm.138.9.1231

Yin Z, Li P, Yu J, Zuo D, Fan H, Li F, et al. Hydroxychloroquine-induced pigmentation in rheumatic diseases: prevalence, clinical features and influencing factors. Rheumatology. 2024; 217:1-9. https://doi.org/10.1093/rheumatology/keae217

Van Beek MJ, Piette WW. Antimalarials. Dermatol Clin. 2001 Jan;19(1):147-60 https://doi.org/10.1016/s0733-8635(05)70236-9

Tselios K, Gladman DD, Harvey P, Mak S, Chantal M, Butany J, et al. Hydroxychloroquine-induced cardiomyopathy in systemic lupus erythematosus. J Clin Rheumatol. 2016;22:287–8. https://doi.org/10.1097/rhu.0000000000000400

Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM. Cardiac complications attributed to chloroquine and hydroxychloroquine: A systematic review of the literature. Drug Saf. 2018;41:919–31. https://doi.org/10.1007/s40264-018-0689-4

Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, Mavrikakis M. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology. 2003 Jul;110(7):1321-6. https://doi.org/10.1016/s0161-6420(03)00409-3

Wolfe F, Marmor MF (2010) Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res 62(6):775–784 https://doi.org/10.1002/acr.20133

Yusuf IH, Sharma S, Luqmani R, Downes SM. Hydroxychloroquine retinopathy. Eye. 2017 Jun;31(6):828-45. https://doi.org/10.1038/eye.2016.298

Mirshahi A, Naderan M, Abrishami M. Screening for hydroxychloroquine associated retinopathy: A review. J Clin Diagn Res. 2019;13:NE01–6 https://doi.org/10.7860/jcdr/2019/38079.13029